{
    "nct_id": "NCT00151502",
    "title": "An 80-Week, Randomized, Multi-Center, Parallel-Group, Double-Blind Study of the Efficacy and Safety of Atorvastatin 80 MG Plus an Acetylcholinesterase Inhibitor Versus an Acetylcholinesterase Inhibitor Alone in the Treatment of Mild to Moderate Alzheimer's Disease.",
    "status": "COMPLETED",
    "last_update_time": "2021-02-17",
    "description_brief": "The purpose of this study is to find out if atovastatin, when taken with a cholinesterase inhibitor, is effective for treating Alzheimer's disease.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE3"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "Atorvastatin 80 mg (statin; HMG\u2011CoA reductase inhibitor)",
        "Acetylcholinesterase inhibitor (background therapy; e.g., donepezil)"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The trial tests atorvastatin (a small\u2011molecule statin) added to standard cholinesterase inhibitor therapy to treat mild\u2013moderate Alzheimer\u2019s disease, which indicates the study is evaluating a small\u2011molecule drug for effects on the course of AD rather than a biologic, a pure symptomatic psychiatric treatment, or a diagnostic procedure. \ue200cite\ue202turn1search2\ue202turn0search2\ue201",
        "Act (extracted details): The investigational drug is atorvastatin 80 mg (an HMG\u2011CoA reductase inhibitor/statin). The trial uses background acetylcholinesterase inhibitor therapy (e.g., donepezil) as the comparator. Atorvastatin\u2019s mechanism (HMG\u2011CoA reductase inhibition; lipid\u2011lowering, with proposed vascular/anti\u2011inflammatory effects) is consistent with a small\u2011molecule class. \ue200cite\ue202turn0search7\ue202turn1search0\ue201",
        "Reflect (classification rationale and caveats): I classify this as \"disease\u2011targeted small molecule\" because atorvastatin is a small molecule being tested for efficacy in AD (hypothesized to influence disease processes via cholesterol/vascular/inflammatory pathways). It is not a biologic (e.g., monoclonal antibody or vaccine), nor is the trial primarily testing a symptomatic cognitive enhancer or an intervention aimed at neuropsychiatric behavior alone. Note: statins are not classical anti\u2011amyloid/tau biologics \u2014 their proposed benefit in AD is indirect (lipid/vascular/inflammatory modulation), but the intervention is still a small\u2011molecule therapy aimed at altering disease course. \ue200cite\ue202turn1search1\ue202turn0search2\ue201",
        "Supporting web search results used: LEADe/atorvastatin in AD randomized trial description and results (trial of atorvastatin + donepezil in mild\u2013moderate AD). \ue200cite\ue202turn1search0\ue202turn1search2\ue201",
        "Supporting pharmacology sources: Atorvastatin is an HMG\u2011CoA reductase inhibitor (statin) \u2014 mechanism and class descriptions. \ue200cite\ue202turn0search2\ue202turn0search7\ue201"
    ],
    "agent_type": "C) ApoE, Lipids and Lipoprotein Receptors",
    "explanation_agent": [
        "Reason: The investigational agent is atorvastatin, a small\u2011molecule HMG\u2011CoA reductase inhibitor (statin) whose primary pharmacologic action is to lower cholesterol and alter lipid metabolism; the trial tests atorvastatin added to background acetylcholinesterase inhibitor therapy in mild\u2013moderate AD, i.e., the intervention targets lipid/cholesterol pathways (and related vascular/anti\u2011inflammatory effects) rather than amyloid or tau directly. \ue200cite\ue202turn0search7\ue202turn0search0\ue201",
        "Act: Extracted details from the trial description \u2014 investigational drug: atorvastatin 80 mg (HMG\u2011CoA reductase inhibitor/statin); comparator/background therapy: acetylcholinesterase inhibitor (e.g., donepezil). Because the drug\u2019s mechanism is lipid\u2011lowering and modulation of lipoprotein biology, the most specific CADRO category is C) ApoE, Lipids and Lipoprotein Receptors. Supporting trial evidence (LEADe) describes atorvastatin 80 mg/day added to donepezil in mild\u2013moderate AD. \ue200cite\ue202turn0search0\ue202turn0search3\ue201",
        "Reflect: Confirmation and caveats \u2014 atorvastatin\u2019s canonical target (HMG\u2011CoA reductase leading to reduced cholesterol/LDL) maps to lipid pathways and to CADRO\u2019s ApoE/Lipids/Lipoprotein Receptors domain rather than to symptomatic neurotransmitter modulation or to amyloid/tau direct targeting. The background use of an acetylcholinesterase inhibitor is symptomatic therapy but does not change the trial drug\u2019s mechanistic classification. Large trials (LEADe) ultimately did not show clinical benefit, but that outcome does not change the mechanistic classification. \ue200cite\ue202turn0search7\ue202turn0search0\ue202turn0search8\ue201",
        "Web search results used: Neurology (LEADe randomized trial of atorvastatin in mild\u2013moderate AD). \ue200cite\ue202turn0search0\ue201",
        "Atorvastatin pharmacology / HMG\u2011CoA reductase inhibitor mechanism (PubMed / drug reviews). \ue200cite\ue202turn0search7\ue201",
        "Alzforum summary of atorvastatin clinical development in AD (LEADe, pilot studies). \ue200cite\ue202turn0search3\ue201",
        "Systematic review/meta\u2011analysis of atorvastatin trials in AD. \ue200cite\ue202turn0search8\ue201"
    ]
}